Side-by-side comparison of AI visibility scores, market position, and capabilities
Glendale CA pressure-sensitive labels and RFID (NYSE: AVY) ~$8.8B FY2024 revenue (+4%); Embelex RFID intelligent labels, Walmart fresh food RFID 2027 mandate tailwind competing with CCL Industries and UPM Raflatac.
Avery Dennison Corporation is a Glendale, California-based materials science and manufacturing company — publicly traded on the New York Stock Exchange (NYSE: AVY) as an S&P 500 Materials component — producing pressure-sensitive label and packaging materials, intelligent labels (RFID, NFC), retail branding and information solutions, and industrial and automotive performance materials through approximately 35,000 employees in 50+ countries. In fiscal year 2024, Avery Dennison reported revenues of approximately $8.8 billion (+4% year-over-year), with the Materials Group segment (pressure-sensitive labeling materials — the adhesive coated paper and film stock that brand owners convert into product labels) and the Solutions Group segment (intelligent labels — RFID tags, apparel branding labels, and digital printing solutions) both contributing to growth. CEO Deon Stander (appointed 2022, previously COO) has accelerated Avery Dennison's "intelligent label" strategy: RFID-enabled product labels (Avery Dennison's Embelex RFID inlays embedded in retail apparel tags, pharmaceutical packaging, and food labels) provide item-level inventory tracking data that retailers (Walmart, H&M, Target), pharmaceutical manufacturers, and food processors use for supply chain visibility, checkout speed, and loss prevention — transitioning Avery Dennison from a materials company to an "information infrastructure" company where each label is a digital data carrier. The 2023 acquisition of LG (formerly known as LG Industries — a label and flexible packaging converter in Southeast Asia and India) expanded Avery Dennison's label converting capabilities in fast-growing Asia Pacific consumer markets.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.